As such, these findings would support the hypothesis that activation of AKT signaling may be a potential mechanism of resistance to treatment with inhibitors of RAS-RAF-MEK-ERK signaling in certain sub-types of HCC. The gene discussed is AKT1; the disease is hepatocellular carcinoma.